CLINICAL TRIALS PROFILE FOR INSULIN DETEMIR
✉ Email this page to a colleague
All Clinical Trials for insulin detemir
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00095082 ↗ | Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2004-09-01 | This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes. |
NCT00097084 ↗ | Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2004-09-01 | This trial is conducted in Europe and the United States of America (USA). The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type 2 diabetes. |
NCT00104182 ↗ | Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2005-02-01 | This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes. |
NCT00106366 ↗ | Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2005-03-01 | This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes. |
NCT00117780 ↗ | Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes | Completed | Novo Nordisk A/S | Phase 4 | 2005-06-01 | This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily injection administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight and side effects). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for insulin detemir
Condition Name
Clinical Trial Locations for insulin detemir
Trials by Country
Clinical Trial Progress for insulin detemir
Clinical Trial Phase
Clinical Trial Sponsors for insulin detemir
Sponsor Name